Ribo Advances Lipid Disorder Strategy with SR122 Trial
Ribo's New Chapter in Lipid Disorders For those keeping tabs on the cutting-edge of lipid research, Ribo’s latest maneuver isn't one to skim over. The company, hailing from both Suzhou and Sweden, just moved forward by submitting its Phase I Clinical Trial Application in Europe for a fascinating compound: SR122. This development isn’t just another filing; it marks a...
Continue Reading